Altered Expression of Cell Cycle-Regulatory Tumor Suppressor Proteins in Neuroendocrine Lung tumors : Their Significance for the Differential Diagnosis
Altered Expression of Cell Cycle-Regulatory Tumor Suppressor Proteins in Neuroendocrine Lung tumors : Their Significance for the Differential Diagnosis
批准号:
11670558
负责人:
AKITA Hirotoshi
金额:
$2.11万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2000
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Neuroendocrine neoplasms of the lung represent a wide spectrum of phenotypically and biologically distinct entities. Their histopathological diagnosis, which carries therapeutic and prognostic significance, may sometimes be difficult because of their overlapping features. We have previously demonstrated that large cell neuroendocrine carcinomas (LCNECs) and small cell lung cancers (SCLCs) failed to show positive nuclear staining of RB protein (RB-), while typical and atypical carcinoids (TCs and ACs) showed nuclear RB immunostaining (RB+) (Cagle, P.T., et al. Am. J.Pathol., 150 : 393, 1997). In the present study, a series of 58 surgically resected lung tumors, of which 33 tumors were initially diagnosed as SCLCs and 25 as TCs or ACs, were studied for RB and p16 protein expression by immunohistochemistry. They were also reviewed for their pathological diagnosis blinded to the RB and p16 protein status. Nineteen tumors were diagnosed as TCs, five as ACs, seven as LCNECs, and 27 as SCLCs. Three of seven LCNECs were RB+, while the other four were RB-. In contrast, all 19 TCs were RB+ and all 27 SCLCs were RB-. In addition, two of five ACs were RB+, while the other three were RB-. Interestingly, all three RB+ LCNECs and the one RB+ AC tested failed to show nuclear staining of p16 protein in any tumor cells (p16-), although some normal stromal cells showed nuclear staining of p16 protein (p16+) as positive internal controls, indicating loss of p16 function in these tumors. Of note, the three RB+ LCNECs were initially diagnosed as SCLCs and one of the RB- ACs was initially considered to be a TC.With the exception of TCs, tumors were significantly more prevalent in heavy smokers with pack years greater than 20 compared with nonsmokers and light smokers with pack years 【less than or equal】 20 (P<0.01). These findings suggest that all SCLCs and LCNECs have abnormalities in the p16 : RB pathway as do at least certain ACs, whereas the p16 : RB pathway is normal in TCs.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
H.Dosaka-Akita: "Differential RB and p16 protein expression in neuroendocrine tumors of the lung"Cancer. 88・3. 550-556 (2000)
H.Dosaka-Akita:“肺神经内分泌肿瘤中的差异性 RB 和 p16 蛋白表达”癌症 550-556 (2000)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hirotoshi Dosaka-Akita: "Differential Retinoblastoma (RB) and p16^<INK4A> protein expression in neuroendocrine tumors of the lung."Cancer. 88(3). 550-556 (2000)
Hirotoshi Dosaka-Akita:“肺神经内分泌肿瘤中视网膜母细胞瘤 (RB) 和 p16^<INK4A> 蛋白表达的差异。”癌症。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
H.Dosaka-Akita.: "Differential RB and p16 protein expression in neuroendocrine tumors of the lung"Cancer. 88・3. 550-556 (2000)
H.Dosaka-Akita.:“肺神经内分泌肿瘤中RB和p16蛋白的差异表达”癌症88・3(2000)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
H.Dosaka-Akita: "Differential RB and p16 protein expression in neuro-endocrine tumors of the lung"Cancer. 88・3. 550-556 (2000)
H.Dosaka-Akita:“肺神经内分泌肿瘤中的差异 RB 和 p16 蛋白表达”癌症 88・3 (2000)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Alteration of fucosylation and biomarker development in lung cancer
-
批准号:22501029
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.75万
-
财政年份:2010
-
负责人:AKITA Hirotoshi
-
依托单位:
Research on Molecular Therapeutic Targets and Biomarkers for the Diagnosis and Stratification in Lung Cancer
-
批准号:16390231
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.26万
-
财政年份:2004
-
负责人:AKITA Hirotoshi
-
依托单位:
The disribution of ganglioside sialidase on developing mouse tooth germ
-
批准号:13671892
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.79万
-
财政年份:2001
-
负责人:AKITA Hirotoshi
-
依托单位:
The role of cytosolic sialidase in developing enamel organs.
-
批准号:09671845
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.05万
-
财政年份:1997
-
负责人:AKITA Hirotoshi
-
依托单位:
Study for the Development of Therapy Based on the Regulation of the myc Gene Expression in Lung Cancer
-
批准号:09557053
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$7.3万
-
财政年份:1997
-
负责人:AKITA Hirotoshi
-
依托单位:
Therapy of Lung Cancer Based on the Regulation of Gene Expression
-
批准号:08670640
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.41万
-
财政年份:1996
-
负责人:AKITA Hirotoshi
-
依托单位:
Basic Study for The Gene-Targeted Therapy in Lung cancer
-
批准号:05670511
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.41万
-
财政年份:1993
-
负责人:AKITA Hirotoshi
-
依托单位:
Biological Function of Retinoic Acid Receptors in Bronchopulmonary System
-
批准号:03807046
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.22万
-
财政年份:1991
-
负责人:AKITA Hirotoshi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于人参皂苷 Rb1 自组装特性的炎症靶向载药系统设计与研究
-
批准号:ZCLKLZ26H1801
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:许平波
-
依托单位:
人参皂苷Rb2抑制p300介导的赖氨酸 10 位点 SF3A2 乙酰化,调控Fscn1减轻肾脏缺血/再灌注损伤
-
批准号:2026JJ82134
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:张影莉
-
依托单位:
RB-domain函数空间的相关研究
-
批准号:2026JJ60113
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:栾伟
-
依托单位:
三七自毒性皂苷Rb1根际解毒菌筛选及微生态调控作用机制研究
-
批准号:JCZRLH202601320
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
槐耳联合CDK4/6抑制剂调控Cyclin D1-CDK4/6-Rb通路在乳腺癌中的作用及机制研究
-
批准号:2026JJ82715
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:廖妮
-
依托单位:
RB1 调控的 ITGB3-PI3K/Akt/β-catenin 信号通路驱动骨质疏松破骨细胞形成的分子机制研究
-
批准号:2026JJ82440
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:贺蛟
-
依托单位:
基于SIRT5/CYCS信号轴探究人参皂苷Rb2抑制心肌缺血损伤的机制研究
-
批准号:2026JJ81978
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:李宇宁
-
依托单位:
基于星形胶质细胞与神经元间隧道纳米管(TnTs)探讨人参皂甙Rb1参与脑缺血再灌注损伤新的保护机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:陈伟
-
依托单位:
基于m6A甲基化修饰探讨人参皂苷Rb1延缓卵巢早衰的RNA表观遗传机制
-
批准号:JCZRYB202500816
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
面向月球样品的钾长石微区原位Rb-Sr定年方法
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:汪程远
-
依托单位: